Owkin
AI biology company whose K Pro agent answers drug discovery questions on targets, biomarkers and druggability using multimodal patient data
Overview
Owkin says it is building "the first solution that automates AI in biology". Its main product, K Pro, is a multi-agent "AI scientist" for pharma R&D: researchers ask plain-language questions about target prioritization, druggability and biomarkers, an orchestrator picks the right skills, and K Pro answers from public data, Owkin's MOSAIC multimodal dataset and its patient data network (25 million patients across 840 hospitals, per Owkin). K Pro launched as an agentic co-pilot in October 2025; in 2026 AstraZeneca, Sanofi and Servier signed K Pro license deals, and Owkin's Pathology Explorer agent launched with Anthropic's Claude for Healthcare and Life Sciences. Owkin itself says K Pro outputs are hypotheses that need expert review. The company was founded in Paris in 2016 by Thomas Clozel (CEO) and Gilles Wainrib.
The Verdict
Who Should Use Owkin?
Best For
- Biopharma teams prioritizing oncology targets and biomarkers
- Researchers who want to query multimodal patient data in plain language
- Scientists who want to try an AI biology agent free on public datasets
Not Ideal For
- Clinicians looking for a diagnostic tool at the bedside
- Teams that need peer-reviewed validation before relying on AI hypotheses
What's Great
- Free tier lets anyone try K Pro on 19 public datasets
- Large pharma licensees: AstraZeneca, Sanofi, Servier
- Proprietary multimodal data (MOSAIC) on the professional tier
Pricing
View all features & details
K Pro
- Plain-language questions on targets, druggability, biomarkers
- Orchestrator agent that selects skills
- Generates research reports
- MOSAIC multimodal dataset (professional tier)
Milestones
- K Pro launched as agentic co-pilot (Oct 2025)
- Pathology Explorer agent with Claude for Healthcare and Life Sciences (Jan 2026)
- K Pro licenses: AstraZeneca, Sanofi, Servier (2026)
How It Compares
| Feature | Owkin | Tempus AI |
|---|---|---|
| Main AI product | K Pro AI scientist | Tempus One clinical assistant |
| Primary users | Biopharma R&D | Oncologists, pharma |
| Free tier | Yes (public datasets) | No public free tier |
| Own lab testing | No | Yes |
Sources: Owkin · Pathology Explorer (Jan 2026) · The Pharma Letter
Is this your tool? Add a badge